Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results

Bulletin Express

03/24

Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.

The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.

The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1151953506"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151953506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151953506?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151953506","market":"us","top_or_hot":-1,"title":"Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results","media":"Bulletin Express","content":"<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.</p>\n<p>The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.</p>\n<p>The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharmaceuticals Delays Board Meeting to 30 March for Completion of FY2025 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-24 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.</p>\n<p>The postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.</p>\n<p>The board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02563","symbol_name":"華昊中天醫藥-B","start_time":0,"source_url":"","article_id":"1151953506","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151953506","pubTimestamp":1774360861,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02563":"华昊中天医药-B"},"translate_title":"Biostar Pharmaceuticals将董事会会议推迟至3月30日以完成2025财年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":1},"content_text":"Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar Pharmaceuticals) announced that its board of directors has rescheduled the upcoming meeting originally set for 25 March 2026. The session, which will review and approve the consolidated annual results for the financial year ended 31 December 2025 and consider any proposed final dividend, will now take place on 30 March 2026.\nThe postponement was attributed to the additional time required for the company and its auditor to complete the review and finalisation of the FY2025 financial statements.\nThe board composition remains unchanged, comprising six executive and non-executive directors and three independent non-executive directors, with Dr. Tang Li serving as chairman and executive director.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}